Defense World
26 Jul 2026, 06:11 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Kiniksa Pharmaceuticals is projected to report Q2 2026 earnings on July 28th with expected EPS of $0.30 and revenue of $226.49 million. — Earnings reports are primary catalysts for price volatility, and expectations set a benchmark for the market's reaction.
+0.40Insiders sold a total of 628,427 shares worth approximately $32.83 million over the last three months. — Significant insider selling can be interpreted as a lack of confidence in near-term upside, despite the use of 10b5-1 plans.
-0.30Major institutional investors, including Goldman Sachs and Millennium Management, have recently increased their stakes in the company. — Increased institutional accumulation generally signals long-term confidence in the company's fundamentals.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Analysts have recently issued a majority of 'Buy' ratings with price targets ranging up to $72.00. — Strong analyst sentiment and targets above the current price of $62.84 provide a bullish psychological floor.
+0.20Which stocks this story touches
The company beat previous earnings and revenue estimates, has strong institutional buying, and received multiple analyst upgrades and price target increases.
Mentioned only as an institutional investor increasing its stake in another company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Defense World
3h ago
